Home / RDH13 Knockout Cell Lines

RDH13 Knockout Cell Lines

Gene: RDH13

Official Full Name: retinol dehydrogenase 13provided by HGNC

Gene Summary: This gene encodes a mitochondrial short-chain dehydrogenase/reductase, which catalyzes the reduction and oxidation of retinoids. The encoded enzyme may function in retinoic acid production and may also protect the mitochondria against oxidative stress. Alternatively spliced transcript variants have been described. [provided by RefSeq, Mar 2009]

Get A Quote
Products Background

Products

Catalog Number Product Name Species Gene Passage ratio Mycoplasma testing Price
KO30918 RDH13 Knockout cell line (HeLa) Human RDH13 1:3~1:6 Negative Online Inquiry
KO30919 RDH13 Knockout cell line (HCT 116) Human RDH13 1:2~1:4 Negative Online Inquiry
KO30920 RDH13 Knockout cell line (HEK293) Human RDH13 1:3~1:6 Negative Online Inquiry
KO30921 RDH13 Knockout cell line (A549) Human RDH13 1:3~1:4 Negative Online Inquiry

Background

RDH13 Gene Knockout Cell Lines represent a state-of-the-art tool in molecular biology designed for the targeted manipulation of gene function. Specifically, these cell lines are engineered to harbor a complete knockout of the RDH13 gene, which encodes for the enzyme retinol dehydrogenase 13, an essential component in the retinoid metabolic pathway.

The primary function of RDH13 is to catalyze the conversion of retinol to retinaldehyde, a crucial step in retinal vitamin A metabolism. By studying these knockout cell lines, researchers can elucidate the specific roles of RDH13 in various biological processes, particularly those associated with vision, cellular signaling, and metabolic diseases. The mechanisms at play can be investigated through various experimental approaches, including gene expression analysis, protein assays, and phenotypic characterizations, allowing for a comprehensive understanding of RDH13's function in vivo.

In clinical research, these cell lines are invaluable for drug discovery and therapeutic developments aimed at diseases linked to retinoid metabolism, such as age-related macular degeneration and certain cancers. They serve as a reliable platform for testing the efficacy of novel therapeutic agents by observing how the absence of RDH13 impacts cellular responses.

Unique advantages of our RDH13 Gene Knockout Cell Lines include their high specificity and reproducibility when compared to alternative models, such as transient knockdown strategies that may exhibit variable gene silencing. Our models are extensively characterized and validated, ensuring that researchers receive consistent and reliable data throughout their studies.

For researchers and clinicians alike, investing in RDH13 Gene Knockout Cell Lines not only enhances the quality of scientific investigations but also accelerates the path to potential clinical applications. With a commitment to excellence in biological research products, our company stands at the forefront of innovation, providing tools that empower the scientific community to advance our understanding of crucial biological mechanisms.

Please note that all services are for research use only. Not intended for any clinical use.

Get a free quote

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.

0

There is no product in your cart.